Pharmasyntez places second Paclical order with Oasmia for $7.5 million

30 October 2015

US oncology specialist Oasmia Pharmaceutical (Nasdaq: OASM) has announced that Pharmasyntez, its distribution partner in Russia and the Commonwealth of Independent States, has placed its second order for Paclical (paclitaxel) to a value of $7.5 million.

This follows the first order to this market for $1.5 million in end-user value, bringing the total of the end-user sales value to over $9 million in commercial orders in one week.

Julian Alexov, executive chairman of Oasmia, said: "We are thrilled that Paclical has been so well received in Russia and CIS. These positive initial orders are a reflection of the market's confidence in the product. We are confident in imminent sales growth as the product continues to garner interest for its ability to enable higher doses, shorten infusion time, eliminate the need for pre-medication and improve the safety profile for patients compared to the available standard treatments."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK